Navigation Links
ULURU Inc. Reports First Quarter 2013 Financial Results
Date:5/16/2013

012.  The increase of approximately $107,000 is primarily attributable to costs associated with our convertible debt and interest costs related to regulatory fees.

Mr. Gray continued, "Revenue was in line with our 2013 financial plan. Continued expense reductions resulted in our net loss being below both the projected level and 2012. With our revised expense base, modest increases in revenue will enable the Company to achieve profitability."

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the advancement of licensing discussions for additional markets, the anticipated launch of Altrazeal® in various markets and countries, the completion of strategic alliances, the anticipated escalation of revenues in 2013, and the acceptance of Altrazeal® by medical practitioners.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve subs
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
2. ULURU Inc. Reports Second Quarter 2012 Financial Results
3. ULURU Inc. Announces First Order Of Altrazeal For European Launch
4. ULURU Inc. Announces The First Shipment Of Veterinary Product
5. ULURU Inc. Reports Third Quarter 2012 Financial Results
6. ULURU Inc. Announces Closing Of $440,000 Private Placement
7. ULURU Inc. Business Update And Outlook
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
9. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
10. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... May 29, 2015 Research and Markets ... the "Global A Dialyzer Reprocessing Machine (A ... to their offering. The Global A ... Report 2014 is a professional and in-depth study ... reprocessing machine industry. The report provides a ...
(Date:6/1/2015)... CAMBRIDGE, Mass. , June 1, 2015  Boston ... compounds designed to target cancer stem cell (CSC) pathways, ... BBI608 and BBI503 in multiple tumor types at the ... in Chicago . Data ... an orally-administered investigational agent that targets STAT3, leading to ...
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
Breaking Medicine Technology:Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... NEW YORK , July 6 Reportlinker.com announces that a ... , , ... and leading players , , ... http://www.reportlinker.com/p0233961/Opportunities-in-Non-Surgical-Bio-Implants-Marketed-injectable-biomaterials-applications-and-leading-players.html , , , ...
... OXFORD, England and LANGHORNE, ... a transatlantic specialty pharmaceutical company focused on,oncology, pain control ... Japanese development and commercialization rights to its oncology therapy,Erwinase(R) ... product partnership EUSA has established in Japan . ...
Cached Medicine Technology:Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 2Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 3Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 4Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 5Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 6Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 7Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 8Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 9Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 10Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 11EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 2EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 3
(Date:6/1/2015)... IPSWICH, Mass. (PRWEB) June 01, 2015 ... decision support solutions, today introduced DynaMed Plus™ , ... and other medical professionals. It provides clinicians with the ... determine optimal patient care paths. , DynaMed Plus ... the market and includes the most frequently updated evidence-based ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 Note: ... new development in breast cancer prevention. , A phase ... suggests that postmenopausal women with ductal carcinoma in situ ... treatment and prevention. , The study (NSABP B-35/NRG Oncology) ... who completed the standard five-year treatment with tamoxifen to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 There’s never a ... when it comes to non-emergency, minor illnesses. , As of ... 24/7 online access to medical care via the Internet. Patients ... smartphone, tablet or computer. , “Everyone is busy. We know ... a challenge, so we want to make it easier,” said ...
(Date:6/1/2015)... Texas (PRWEB) June 01, 2015 Carrick ... brain health landscape on a global level. This ... realms, allowing Carrick Brain Centers to broaden their scope ... healing. , Broadened horizons are accompanied by a restructuring ... 1, 2015, Carrick Brain Centers will separate itself from ...
(Date:6/1/2015)... 01, 2015 A University of ... inhibits signaling proteins that activate protein degradation, which ... exercise. 1 , The study published April ... male Spraque-Dawley rats 2-3 months of age who ... were given either whey protein (.4g/kg), low-dose Sustamine ...
Breaking Medicine News(10 mins):Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3
... PRINCETON, N.J., July 15 Diabetes patients taking ... insulin in their pump for up to six days following ... labeling change, diabetes care company Novo Nordisk announced today.(1) The ... pump reservoir for two days. This makes NovoLog((R)) the first ...
... likely to keep education a priority, research finds , ... more likely than their Chinese counterparts to lose interest ... children outperform Americans in academic pursuits such as math, ... and Chinese students in grades 7 and 8, more ...
... , WASHINGTON, July 15 Steele will ... spelling out what Republicans are for and what they are against while ... care plan would do for ordinary Americans. , ... , The Senate Health, Education, Labor and ...
... 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) ... preparing for the tender business of 250,000 doses of ... can be viewed by visiting this web page directly ... batch exported to Indonesia this year by the company. ...
... WASHINGTON, July 15 Speaker Nancy Pelosi issued the following ... health care reform legislation: , , ... the Senate HELP Committee is further evidence of great momentum in ... of trying, this puts us one step closer to real reforms ...
... , Recent Death of Infant in ... SILVER SPRING, Md., July 15 The American Society for Parenteral ... the science and practice of nutrition support therapy, is saddened by the recent ... to him through an IV catheter and not through a feeding tube in ...
Cached Medicine News:Health News:FDA Approves NovoLog(R) Labeling Update 2Health News:FDA Approves NovoLog(R) Labeling Update 3Health News:FDA Approves NovoLog(R) Labeling Update 4Health News:U.S. Students' Academic Interests Tend to Wane in Middle School 2Health News:Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia 2Health News:Tube Feeding Error: Fatal Medical Mistakes 2Health News:Tube Feeding Error: Fatal Medical Mistakes 3
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... The Shandon Finesse E+ is ... provides automated specimen advance with ... balanced flywheel is easy to ... the user the option of ...
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
... is a service that directly connects ... the customers laboratory to the Thermo ... U.S.A., and Runcorn, U.K.* By using ... customer site, high-value support services are ...
Medicine Products: